Agilent (A) Reports Q4 Earnings: What Key Metrics Have to Say

Agilent Technologies (A) reported $1.7 billion in revenue for the quarter ended October 2024, representing a year-over-year increase of 0.8%. EPS of $1.46 for the same period compares to $1.38 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.67 billion, representing a surprise of +1.65%. The company delivered an EPS surprise of +3.55%, with the consensus EPS estimate being $1.41.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue by End Markets- Pharmaceutical: $595 million compared to the $583.30 million average estimate based on two analysts. The reported number represents a change of +0.9% year over year. Revenue by End Markets- Academia and Government: $150 million versus the two-analyst average estimate of $138.29 million. The reported number represents a year-over-year change of 0%. Revenue by End Markets- Diagnostics and Clinical: $255 million compared to the $243.48 million average estimate based on two analysts. The reported number represents a change of +8.1% year over year. Revenue by End Markets- Chemical and advanced materials: $385 million compared to the $385.60 million average estimate based on two analysts. The reported number represents a change of +1.1% year over year. Net Revenue- Agilent Crosslab Group: $426 million versus $431.46 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.5% change. Revenue by End Markets- Environmental and Forensics: $164 million versus the two-analyst average estimate of $167.03 million. The reported number represents a year-over-year change of -6.3%. Net Revenue- Life Sciences and Applied Markets Group: $833 million versus the two-analyst average estimate of $819.25 million. The reported number represents a year-over-year change of -10.2%. Net Revenue- Diagnostics and Genomics Group: $442 million compared to the $417.75 million average estimate based on two analysts. The reported number represents a change of +24.2% year over year. Revenue by End Markets- Food: $152 million versus $158.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.6% change. View all Key Company Metrics for Agilent here>>>Shares of Agilent have returned +2.8% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks